Loading...
Loading...
Most people who hold private company shares treat them as a future windfall — something to think about when the IPO happens, the acquisition closes, or the tender offer arrives. Far fewer think about what happens to those shares if the holder doesn't make it that far. Yet startup equity in estate planning is one of the messiest topics in modern wealth management. The shares are illiquid, the valuations are contested, the tax rules are unforgiving, and the documents governing them — option grants, vesting schedules, rights of first refusal, transfer restrictions — were often drafted with no thought given to what happens when the holder dies. In this guide, two perspectives — a former venture capital general partner and a senior private wealth manager — walk through how to think about startup equity in estate planning, from valuation traps to liquidity planning to the specific vehicles that work best for illiquid private company shares.
Traditional estate planning assumes assets that can be valued, transferred, and, if necessary, sold. A diversified portfolio of public stocks, a brokerage account, a home — these all have clear market prices and well-trodden legal pathways for transfer at death. Startup equity has none of those properties. It is illiquid, frequently subject to company transfer restrictions, often encumbered by a right of first refusal (ROFR), and valued by a 409A appraisal that may diverge sharply from the price a sophisticated secondary buyer would pay. That mismatch between book-style valuation and real-world marketability is what makes startup equity in estate planning genuinely hard.
From a fund-management vantage point, I have watched estates get stuck for years because the founder's heirs could not actually move the shares — the issuing company refused to consent to a transfer, the secondary market would not touch the position at any price the executor considered fair, and the IRS still wanted the estate tax paid on time. The cleaner the planning done while the holder is alive, the cleaner the outcome for the family. For broader context on how founders should think about their equity over time, our piece on managing startup equity covers the strategic frame; this article zooms in specifically on the wealth-transfer dimension.
The IRS requires every estate to value all property at fair market value (FMV) as of the date of death, or, in some cases, an alternate valuation date six months later. For public securities, that exercise is trivial — the closing price on the exchange controls. For private startup equity, valuation is a battleground. Common approaches include the most recent 409A appraisal, the most recent preferred round price adjusted for common stock discounts, an option pricing method (OPM) backsolve from the latest round, and probability-weighted expected return (PWERM) models for companies that are nearer to an exit. Each method produces a different number — and the spread between the highest and lowest can be substantial.
For any meaningful position, a wealth manager will typically commission an independent business valuation, because the IRS can and does challenge values that look too low. The IRS estate tax guidance is explicit that the gross estate includes everything the deceased person owned at the date of death, including business interests, stock, and stock options. The gap between what an estate reports and what the IRS ultimately accepts is one of the most common reasons private-company estates end up in extended valuation litigation.
Two tax rules dominate startup equity in estate planning, and they pull in opposite directions. The first is the step-up in basis under IRC §1014. Inherited property generally takes a new basis equal to its FMV at the holder's death. If a founder bought common stock at a fraction of a cent and dies when those shares are worth $50 each, the heirs' basis becomes $50, and selling at or near that price produces little or no capital gain. That benefit is enormous — and it is one of the strongest arguments for early exercise and §83(b) elections in the right circumstances, since actual stock (not options) is what qualifies for the step-up.
The second rule is the income-in-respect-of-a-decedent (IRD) doctrine, which is the unfriendly twin. Vested but unexercised non-qualified stock options (NSOs) generally do not receive a basis step-up. When the heirs ultimately exercise, they recognize ordinary income on the spread between exercise price and FMV at exercise, exactly as the original holder would have. Incentive stock options (ISOs) lose their ISO status entirely at death and are treated as NSOs in the heirs' hands. This is one of the single most expensive traps in estate planning stock options, and it almost never reveals itself until the executor sits down with a CPA after the funeral.
In my experience advising employees over the last decade and a half, I have seen too many families discover, post-mortem, that what they thought were appreciated startup options sitting in the estate were actually a giant block of ordinary income waiting to be triggered — with zero step-up to soften the tax blow. That is the single biggest reason estate planning stock options need to be reviewed by a tax professional, not just a generalist trust-and-estates attorney. The U.S. tax code's treatment of survivors and executors is detailed in the IRS Publication 559, which is essential reading for anyone administering a startup employee's estate.
Passing startup equity to heirs efficiently almost always means using one or more specialized vehicles, each with distinct trade-offs in cost, complexity, control, and tax outcome. Below are the structures that come up most often in real planning conversations.
Revocable living trust. The simplest tool. The holder transfers shares into a trust during life; on death, the trust avoids probate and distributes according to its terms. No transfer-tax benefit, but it shields privacy and speeds administration. Most startup companies will consent to a transfer into a revocable trust if the trust is for the holder's own benefit during life.
Grantor Retained Annuity Trust (GRAT). A favorite of founders with rapidly appreciating shares. The holder transfers stock to the trust in exchange for an annuity stream; if the shares grow faster than the IRS §7520 hurdle rate, the excess passes to heirs gift-tax-free. GRATs are most powerful immediately before a major up-round or a public listing — and least useful for shares that may eventually go to zero.
Family Limited Partnership (FLP) or family LLC. Holding startup equity in an FLP allows valuation discounts for lack of marketability and lack of control when interests pass to heirs, and consolidates voting and consent rights in one entity. Discounts of 20–35% are common, though aggressive discounts attract IRS scrutiny and should be supported by a qualified appraisal.
Intentionally Defective Grantor Trust (IDGT). Sells equity to a grantor trust in exchange for a promissory note; future appreciation grows outside the estate while income tax is still paid by the grantor (a feature, not a bug). Powerful for high-net-worth founders but requires sophisticated drafting and ongoing administration.
Outright lifetime gifts. Use the annual gift exclusion (indexed annually) or the lifetime exemption to give shares directly to heirs while the holder is alive. Best done when the valuation is low — typically the earliest stages of the company, before priced rounds compress the discount between common and preferred. Once the cap table starts moving, gifting costs jump dramatically.
Federal estate tax is due nine months after death. For estates that exceed the lifetime exemption, the marginal rate climbs to 40%. For a founder or long-tenured executive whose net worth is 80–90% locked up in startup equity, that creates an obvious problem: the estate may owe millions in cash while owning shares that cannot be sold without company consent and may have no available buyer at the time the bill comes due.
Common liquidity solutions include life insurance held in an irrevocable life insurance trust (ILIT), structured tender offer rights negotiated in advance with the company, IRC §6166 elections to pay estate tax in installments over up to 14 years for closely held business interests, and — increasingly — equity pooling arrangements that convert single-stock exposure into diversified portfolio exposure with a cleaner marketability profile. For a deeper look at why diversification matters here, see our introduction to equity pooling.
Passing startup equity to heirs without a deliberate liquidity plan is the single most common failure mode I have seen across two decades of wealth-management practice. Families end up forced into bad secondary sales at fire-sale prices, or into rushed §6166 elections that lock the estate into years of administration, simply to meet the nine-month estate-tax deadline. Cash needs to be planned for; it does not appear spontaneously.
Vested stock options present their own set of issues in startup equity in estate planning. Most option plans terminate options on death within a short post-death exercise window — sometimes as little as 90 days, more commonly six to twelve months. If the plan does not permit transfer, the options simply expire. If the plan does permit transfer to a trust or to heirs, the recipient must exercise within the post-death window and find the cash to do so. For ISOs in particular, the holder loses preferential tax treatment, so what looked like a tax-efficient asset during life can become an ordinary-income event for the heirs.
Restricted stock that vests under a §83(b) election generally passes to heirs cleanly with a stepped-up basis. Unvested restricted stock typically forfeits at death unless the agreement provides for accelerated vesting or extended exercise periods — the so-called death-and-disability provisions. Reviewing every plan document on a grant-by-grant basis is non-negotiable; assumptions do not survive contact with the actual paperwork. Our guide on whether to buy your equity walks through the live-holder version of the same calculus.
Putting all of the above together, here is the practical sequence we recommend clients follow. None of these steps require unusual sophistication; what they require is the time and discipline to do them before the planning becomes reactive instead of proactive.
1. Inventory. List every grant, every plan document, every transfer restriction, every ROFR. Most holders cannot answer this from memory, and executors certainly cannot.
2. Read the plan documents on death. Find the post-death exercise window for every option grant. Note any transfer or beneficiary designation rights. If anything is unclear, write to the company's stock administrator and get the answer in writing.
3. Get a current, defensible valuation. Either a recent 409A or an independent appraisal report that the executor can rely on later. Update annually for active holders.
4. Choose vehicles. Coordinate with a trust-and-estates attorney on the right mix of revocable trust, GRAT, IDGT, ILIT, and FLP structures based on the size of the position and the stage of the underlying company.
5. Plan liquidity. Map specific sources of cash sufficient to meet the nine-month estate tax window. Do not assume the company will consent to a secondary sale on the executor's timetable.
6. Diversify where possible. Concentrated positions amplify every estate-planning risk — valuation disputes, liquidity shortfalls, ordinary-income exposure via IRD. Diversification is the single biggest structural lever available; tools like our equity simulator let holders model the effect of converting some single-stock exposure into a pooled portfolio.
Across the combined two-plus decades of fund management and private wealth practice represented in this article, the failure modes are remarkably consistent. The most common, in rough order of cost to the family: treating NSOs as if they receive a stepped-up basis (they do not); letting options lapse unexercised during the post-death window because no one in the family read the plan documents; filing an estate-tax valuation that ignores the most recent secondary trade or tender-offer price; skipping insurance and leaving heirs with an unfunded estate-tax bill; and failing to update beneficiary designations on equity grants after major life events such as marriage, divorce, or the birth of additional children. Every one of these is fixable while the holder is alive. None is fixable afterward.
Startup equity in estate planning sits at the intersection of three of the most technical areas in personal finance — illiquid securities, federal transfer tax, and venture-backed company governance. The default outcome, if nothing is done in advance, is almost always worse than the planned outcome. Inventories take a weekend. Trust documents take a few months. Liquidity planning can take years to fund properly. The cost of doing nothing — to heirs, to the family, to the share value itself — is real, measurable, and entirely avoidable with reasonable foresight.
At Aption, we work with employees, founders, and their advisors on the diversification side of this equation. Pooling startup equity converts a single-stock estate into exposure to a portfolio of high-growth private companies, which materially changes the valuation, liquidity, and risk profile that an estate planner has to work around. If you would like to see how pooling could fit into your overall picture, the equity simulator is the easiest place to start, and our advisor resources are designed specifically for the trust-and-estates attorneys, CPAs, and wealth managers who tend to quarterback these decisions across multiple generations of a family.
The author name used in this article may be a pen name or pseudonym and is used for illustrative and editorial purposes only. This article is for informational purposes only and does not constitute investment, tax, or legal advice. Tax laws, exemption amounts, and IRS rules referenced may change; figures cited reflect publicly available guidance at the time of writing. Consult qualified professionals — including a trust-and-estates attorney, CPA, and licensed financial advisor — before making decisions about startup equity in estate planning or any related matters.
Daniel is a former venture capital partner and startup equity strategist with over 15 years of experience advising founders, employees, and institutional investors on equity structures, liquidity events, and portfolio construction.